<DOC>
	<DOCNO>NCT01544296</DOCNO>
	<brief_summary>This placebo-controlled , double blind , crossover study evaluate efficacy safety KHK6188 postherpetic neuralgia administer orally 2 week .</brief_summary>
	<brief_title>A Comparative Study KHK6188</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<criteria>Patients pain ≥ 3 month ≤ 1 year follow onset herpes zoster rash Patients mean pain intensity score ( 11point numerical rating scale ) ≥ 4 Patients whose rash heal Patients able fill patient diary Patients provide write voluntary inform consent participate study Patients pain disease may impair self assessment pain Patients dementia , depression schizophrenia may affect self assessment pain History presence severe cardiovascular disease , hepatic dysfunction , renal failure , respiratory disease , blood disease CNS disorder History presence drug allergy Patients history diagnosis cancer treatment cancer within 5 year prior study entry Patients receive investigational medication within 4 month ( 6 month biologic medication antibody ) prior inform consent Women child bear potential agree avoid pregnancy time provide consent 3 month end dose , men reproductive potential agree avoid pregnancy time first dose 3 month end dose Patients pregnant , lactate , possibly pregnant Patients judge inappropriate enter study investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>